Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study

Invest New Drugs. 1993 Feb;11(1):81-3. doi: 10.1007/BF00873917.

Abstract

Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioguanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioguanine is not felt to have significant antitumor activity in this patient population.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Aged
  • Carcinoma, Small Cell / drug therapy*
  • Drugs, Investigational / administration & dosage*
  • Drugs, Investigational / adverse effects
  • Female
  • Humans
  • Infusions, Intravenous
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Prognosis
  • Thioguanine / administration & dosage*
  • Thioguanine / adverse effects
  • Time Factors

Substances

  • Drugs, Investigational
  • Thioguanine